Patents by Inventor Gayle Taylor

Gayle Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8193365
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Grant
    Filed: June 14, 2010
    Date of Patent: June 5, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter J. Sinclair, Gayle Taylor, Christopher Thompson, Nazia Quraishi
  • Publication number: 20070225365
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula 1, A1 and A2 are each an aromatic ring, a 5-6-membered heterocyclic ring, an aromatic ring fused to a heterocyclic ring, a phenyl ring fused to a heterocyclic ring, or a cycloalkyl ring.
    Type: Application
    Filed: April 8, 2005
    Publication date: September 27, 2007
    Applicant: MERCK & CO., INC.
    Inventors: Amjad Ali, Joann Bohn, Qiaolin Deng, Zhijian Lu, Peter Sinclair, Gayle Taylor, Christopher Thompson, Nazia Quraishi
  • Publication number: 20060063746
    Abstract: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharamaceutical compositions and methods of use are also included.
    Type: Application
    Filed: January 16, 2004
    Publication date: March 23, 2006
    Inventors: Amjad Ali, James Balkovec, Donald Graham, Mark Greenlee, Gayle Taylor
  • Publication number: 20060040999
    Abstract: Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or R2 is a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a —CH2—.
    Type: Application
    Filed: July 1, 2005
    Publication date: February 23, 2006
    Inventors: Amjad Ali, Joann Napolitano, Qiaolin Deng, Zhijian Lu, Peter Sinclair, Gayle Taylor, Christopher Thompson, Nazia Quraishi, Cameron Smith, Julianne Hunt, Adrian Dowst, Yi-Heng Chen, Hong Li
  • Publication number: 20050245588
    Abstract: The present invention encompasses compounds of Formula I: or pharmaceutically acceptable salts or hydrates thereof, which are useful as selective glucocorticoid receptor ligands for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: September 17, 2003
    Publication date: November 3, 2005
    Inventors: Amjad Ali, Susan Aster, James Balkovec, Donald Graham, Julianne Hunt, Florida Kallashi, Peter Sinclair, James Tata, Gayle Taylor, Joung Goulet